|
1
|
Chen WQ, Zhang SW, Zou XN and Zhao P:
Cancer incidence and mortality in China, 2006. Chin J Cancer Res.
23:3–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, Friedlander M, et al: Rethinking ovarian cancer:
Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brouwer-Visser J, Lee J, McCullagh K,
Cossio MJ, Wang Y and Huang GS: Insulin-like growth factor 2
silencing restores taxol sensitivity in drug resistant ovarian
cancer. PLoS One. 9:e1001652014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY,
Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression
of forkhead box protein M1 (FOXM1) in ovarian cancer correlates
with poor patient survival andcontributes to paclitaxel resistance.
PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goulet B, Baruch A, Moon NS, Poirier M,
Sansregret LL, Erickson A, Bogyo M and Nepveu A: A cathepsin L
isoform that is devoid of a signal peptide localizes to the nucleus
in S phase and processes the CDP/Cux transcription factor. Mol
Cell. 14:207–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruan J, Zheng H, Fu W, Zhao P, Su N and
Luo R: Increased expression of cathepsin L: A novel independent
prognostic marker of worse outcome in hepatocellular carcinoma
patients. PLoS One. 9:e1121362014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zajc I, Hreljac I and Lah T: Cathepsin L
affects apoptosis of glioblastoma cells: A potential implication in
the design of cancer therapeutics. Anticancer Res. 26:3357–3364.
2006.PubMed/NCBI
|
|
8
|
Zheng X, Chu F, Chou PM, Gallati C, Dier
U, Mirkin BL, Mousa SA and Rebbaa A: Cathepsin L inhibition
suppresses drug resistance in vitro and in vivo: A putative
mechanism. Am J Physiol Cell Physiol. 296:C65–C74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Primon M, Huszthy PC, Motaln H, Talasila
KM, Torkar A, Bjerkvig R and Lah Turnšek T: Cathepsin L silencing
enhances arsenic trioxide mediated in vitro cytotoxicity and
apoptosis in glioblastomaU87MG spheroids. Exp Cell Res.
319:2637–2648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Wei L, Shen G, He B, Gong W, Min
N, Zhang L, Duan Y, Xie J, Luo H and Gao X: Cathepsin L is involved
in proliferation and invasion of ovarian cancer cells. Mol Med Rep.
11:468–474. 2015.PubMed/NCBI
|
|
11
|
Jiang L, Siu MK, Wong OG, Tam KF, Lu X,
Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, et al: iASPP and
chemoresistance in ovarian cancers: Effects on paclitaxel-mediated
mitotic catastrophe. Clin Cancer Res. 17:6924–6933. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deraco M, Baratti D, Laterza B, Balestra
MR, Mingrone E, Macrì A, Virzì S, Puccio F, Ravenda PS and Kusamura
S: Advanced cytoreduction as surgical standard of care and
hyperthermic intraperitoneal chemotherapy as promising treatment in
epithelial ovarian cancer. Eur J SurgOncol. 37:4–9. 2011.
View Article : Google Scholar
|
|
13
|
Chauhan SS, Goldstein LJ and Gottesman MM:
Expression of cathepsin L in human tumors. Cancer Res.
51:1478–1481. 1991.PubMed/NCBI
|
|
14
|
Zhang W, Wang S, Wang Q, Yang Z, Pan Z and
Li L: Overexpression of cysteine cathepsin L is a marker of
invasion and metastasis in ovarian cancer. Oncol Rep. 31:1334–1342.
2014.PubMed/NCBI
|
|
15
|
Stoka V1, Turk B, Schendel SL, Kim TH,
Cirman T, Snipas SJ, Ellerby LM, Bredesen D, Freeze H, Abrahamson
M, et al: Lysosomal protease pathways to apoptosis. Cleavage of
bid, not pro-caspases, is the most likely route. J Biol Chem.
276:3149–3157. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu M, Yang L, Rong JG, Ni Y, Gu WW, Luo Y,
Ishidoh K, Katunuma N, Li ZS and Zhang HL: Inhibition of cysteine
cathepsin B and L activation in astrocytes contributes to
neuroprotection against cerebral ischemia via blocking the
tBid-mitochondrial apoptotic signaling pathway. Glia. 62:855–880.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wille A, Gerber A, Heimburg A, Reisenauer
A, Peters C, Saftig P, Reinheckel T, Welte T and Bühling F:
Cathepsin L is involved in cathepsin D processing and regulation of
apoptosis in A549 human lung epithelial cells. Biol Chem.
385:665–670. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Walz M, Kellermann S, Bylaite M, Andrée B,
Rüther U, Paus R, Kloepper JE, Reifenberger J and Ruzicka T:
Expression of the human Cathepsin L inhibitor hurpin in mice: Skin
alterations and increased carcinogenesis. Exp Dermatol. 16:715–723.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levicar N, Dewey RA, Daley E, Bates TE,
Davies D, Kos J, Pilkington GJ and Lah TT: Selective suppression of
cathepsin L by antisense cDNA impairs human brain tumor cell
invasion in vitro and promotes apoptosis. Cancer Gene Ther.
10:141–151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kenig S, Frangež R, Pucer A and Lah T:
Inhibition of cathepsin L lowers the apoptotic threshold of
glioblastoma cells by up-regulating p53 and transcription of
caspases 3 and 7. Apoptosis. 16:671–682. 2011. View Article : Google Scholar : PubMed/NCBI
|
